NextPlat (NASDAQ:NXPL) Releases Quarterly Earnings Results

NextPlat (NASDAQ:NXPL) posted its quarterly earnings results on Thursday. The company reported ($0.42) EPS for the quarter, Zacks reports. NextPlat had a negative return on equity of 53.22% and a negative net margin of 21.56%.

Here are the key takeaways from NextPlat’s conference call:

• NextPlat said its turnaround is largely complete, with Q1 showing record-level gross margins, lower operating expenses, and a clear path to improving profitability in the second half of 2026.
• The healthcare segment posted a major improvement, with gross margin rising to 39% from about 20% a year ago and the segment generating positive operating income for the quarter.
• The company secured five new 340B pharmacy service agreements in the quarter, a record, and expects those customers to begin contributing to revenue in the third quarter after onboarding.
• Management highlighted new growth initiatives, including a nationwide fulfillment partnership and a planned e-commerce healthcare site that will sell prescription drugs, GLP-1 products, and OTC items, expected to launch before the end of Q2.
• Quarterly revenue declined year over year to about $10 million, though the company said the mix is shifting toward higher-margin contract and fulfillment revenue, while e-commerce remained steady at about $3.2 million.

NextPlat Price Performance

Shares of NASDAQ:NXPL traded down $0.15 during trading on Thursday, hitting $6.26. 16,641 shares of the company were exchanged, compared to its average volume of 12,016. NextPlat has a 1-year low of $3.38 and a 1-year high of $11.10. The company has a market capitalization of $16.96 million, a P/E ratio of -1.42 and a beta of 1.91. The company has a quick ratio of 2.27, a current ratio of 2.65 and a debt-to-equity ratio of 0.05. The business’s 50 day moving average is $5.42 and its 200-day moving average is $6.07.

Hedge Funds Weigh In On NextPlat

A hedge fund recently bought a new stake in NextPlat stock. Citadel Advisors LLC purchased a new stake in shares of NextPlat Corp. (NASDAQ:NXPL) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 48,176 shares of the company’s stock, valued at approximately $40,000. Citadel Advisors LLC owned approximately 0.19% of NextPlat at the end of the most recent quarter. 1.30% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings raised NextPlat from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

NextPlat Company Profile

NextPlat Corp operates as a healthcare and e-commerce company in Europe, North America, South America, the Asia and Pacific, and Africa. The company operates full-service retail specialty services pharmacies that provides prescription pharmaceuticals prescription pharmaceuticals, third-party administration, risk and data management services, compounded medications, tele-pharmacy services, anti-retroviral medications, medication therapy management, contracted pharmacy services, and health practice risk management to healthcare organizations and providers, as well as supplies prescription medications to long-term care facilities.